News | March 12, 2022
Terran Biosciences acquires Concert’s CNS therapeutics portfolio
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
The product will be manufactured at Lupin’s facility in Goa, India
The Gujarat Biotechnology policy released last month has made radical changes to position the state as a biotechnology hub. It already has a thriving ecosystem of pharma companies and varied suppliers
The RI investment comes on the back of three other recently completed transactions in Malaysia and Singapore in the last two months
The Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (UZH) and Insilico Medicine will be working together to identify, rank, and annotate novel drug targets to identify potential therapeutics for cystinosis
Breakthrough formulation helps reduce the risk of exposure using a non-hazardous formulation and leakproof format during transport and processing
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
Internationally accepted pharmaceutical GDP regulations stipulate that distributors of pharmaceutical products and warehouses must align their operations with the specified standards
Subscribe To Our Newsletter & Stay Updated
